An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin®) in Combination With Chemotherapy.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01333007

Enrollment

423

Registered

2011-04-11

Start date

2010-07-31

Completion date

2013-05-31

Last updated

2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Brief summary

This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients, \>/= 18 years of age * Inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) * Treating physician's decision to initiate first-line Avastin treatment

Exclusion criteria

* Participation in a clinical trial evaluating anti-cancer therapies

Design outcomes

Primary

Measure	Time frame
Progression-free survival	18 months

Secondary

Measure	Time frame
Modality of treatment with Avastin (dose, duration, associated chemotherapy)	18 months
Overall survival	18 months
Clinical (diagnosis, therapies, comorbidity) and demographic characteristics of patients initiated on Avastin treatment	18 months
Quality of Life: Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire	18 months
Treatment of non-squamous NSCLC in clinical practice	18 months
Safety: Incidence of adverse events	18 months

Countries

France

Outcome results